anti-CD19 CAR-T cells

also known as MB-CART19.1 · anti-CD19-CAR-transduced T cells · CD19 CAR T-cells · CD19-targeting CAR T Cells · UWD-CD19

Developed for: systemic lupus erythematosus · B-cell acute lymphoblastic leukemia · systemic sclerosis · B-cell neoplasm · Sjogren syndrome · anti-neutrophil cytoplasmic antibody-associated vasculitis · B-cell non-Hodgkin lymphoma · childhood acute lymphoblastic leukemia
+22 more
· chronic lymphocytic leukemia/small lymphocytic lymphoma · diffuse large B-cell lymphoma · idiopathic inflammatory myopathy · lymphoma · mantle cell lymphoma · primary mediastinal large B-cell lymphoma · rheumatoid arthritis · acute lymphoblastic leukemia · adult acute lymphoblastic leukemia · antiphospholipid syndrome · B-cell chronic lymphocytic leukemia · Burkitt lymphoma · follicular lymphoma · Hodgkins lymphoma · large B-cell lymphoma · leukemia · lymphoid leukemia · lymphoplasmacytic lymphoma · myositis disease · non-Hodgkin lymphoma · primary central nervous system lymphoma · steroid-resistant nephrotic syndrome
Investigated by: Miltenyi Biomedicine GmbH · The Children's Hospital of Zhejiang University School of Medicine · National Cancer Institute (NCI) · Shanghai First Song Biotechnology Co., LTD · Shanghai GeneChem Co., Ltd. · Affiliated Hospital of Nantong University
+29 more
· C. Babis Andreadis · Chongqing Precision Biotech Co., Ltd · First Affiliated Hospital of Wenzhou Medical University · Fuda Cancer Hospital, Guangzhou · Guangzhou Women and Children's Medical Center · Gustave Roussy, Cancer Campus, Grand Paris · Huntsman Cancer Institute/ University of Utah · KK Women's and Children's Hospital · King Hussein Cancer Center · Lentigen Technology, Inc. · Memorial Sloan Kettering Cancer Center · National Institute of Hematology and Blood Transfusion, Vietnam · Peking University · Peking University Third Hospital · RenJi Hospital · Shanghai Children's Medical Center · Shanghai First Song Therapeutics Co., Ltd · Shanghai Tongji Hospital, Tongji University School of Medicine · Singapore General Hospital · Southwest Hospital, China · The Affiliated Hospital of Xuzhou Medical University · The First Affiliated Hospital of Anhui Medical University · The First Affiliated Hospital of University of Science and Technology of China · University Hospital, Montpellier · University of California, Davis · University of Florida · University of Utah · Vinmec Research Institute of Stem Cell and Gene Technology · Yan'an Affiliated Hospital of Kunming Medical University

Trials 30 · a red edge is where a trial was stopped

today NCT07544225 · Ph 1 NCT07493395 · Ph 2 NCT07371403 · not/applicable NCT07137494 · Ph 1 NCT06842589 · Ph 1 NCT06821659 · Ph 1/2 NCT06792344 · Ph 1 NCT06189157 · Ph 1/2 NCT06420154 · Ph 0 NCT06508775 · not/applicable NCT06227026 · Ph 1 NCT06222853 · Ph 1 NCT06375161 · Ph 0 NCT06503237 · not/applicable NCT06756321 · Ph 0 NCT06532630 · Ph 0 NCT06027957 · Ph 1 NCT05744037 · Ph 2 NCT05648019 · Ph 2 NCT04545762 · Ph 1 NCT04289220 · Ph 1 NCT03853616 · Ph 1 NCT03321123 · Ph 2 NCT03030976 · Ph 1 NCT02737085 · Ph 1/2 NCT02672501 · Ph 1/2 NCT02547948 · Ph 1/2 NCT02247609 · Ph 1/2 NCT01087294 · Ph 1 NCT00924326 · Ph 1/2

200920102011201220132014201520162017201820192020202120222023202420252026202720282029203020312032203320342035203620372038203920402041

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 04 trials
Phase 0	NCT06420154	May 2024 → May 2027 expected	Sjogren syndrome, anti-neutrophil cytoplasmic antibody-associated vasculitis, antiphospholipid syndrome, myositis disease +2	First Affiliated Hospital of Wenzhou Medical University	Not yet recruiting	No outcome recorded
Phase 0	NCT06375161	Dec 2023 → Dec 2025 overdue	B-cell neoplasm	Shanghai Tongji Hospital, Tongji University School of Medicine	Recruiting	No outcome recorded
Phase 0	NCT06756321	Sep 2023 → Mar 2025 overdue	leukemia, lymphoma	Affiliated Hospital of Nantong University	Recruiting	No outcome recorded
Phase 0	NCT06532630	Aug 2023 → Sep 2025 overdue	B-cell neoplasm	Shanghai First Song Biotechnology Co., LTD	Recruiting	No outcome recorded
Phase 112 trials
Phase 1	NCT07544225	Sep 2026 → Feb 2029 expected	Sjogren syndrome, idiopathic inflammatory myopathy, rheumatoid arthritis, systemic lupus erythematosus +1	Gustave Roussy, Cancer Campus, Grand Paris	Not yet recruiting	No outcome recorded
Phase 1	NCT07137494	Aug 2025 → Aug 2028 expected	primary central nervous system lymphoma	Memorial Sloan Kettering Cancer Center	Recruiting	No outcome recorded
Phase 1	NCT06842589	May 2025 → Feb 2027	steroid-resistant nephrotic syndrome	The Children's Hospital of Zhejiang University School of Medicine	Withdrawn	No outcome recorded
Phase 1	NCT06792344	Dec 2024 → Dec 2027 expected	systemic sclerosis	The Children's Hospital of Zhejiang University School of Medicine	Recruiting	No outcome recorded
Phase 1	NCT06227026	Feb 2024 → Jul 2026 overdue	acute lymphoblastic leukemia, diffuse large B-cell lymphoma	University of Utah	Recruiting	No outcome recorded
Phase 1	NCT06222853	Feb 2024 → Apr 2025 overdue	systemic lupus erythematosus	The Children's Hospital of Zhejiang University School of Medicine	Active not recruiting	No outcome recorded
Phase 1	NCT06027957	Aug 2023 → Jun 2025	B-cell acute lymphoblastic leukemia	Vinmec Research Institute of Stem Cell and Gene Technology	Completed	No outcome recorded
Phase 1	NCT04545762	Sep 2020 → Oct 2026 expected	Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma +2	C. Babis Andreadis	Recruiting	No outcome recorded
Phase 1	NCT04289220	Mar 2020 → Mar 2023	B-cell acute lymphoblastic leukemia	Yan'an Affiliated Hospital of Kunming Medical University	Unknown	No outcome recorded
Phase 1	NCT03853616	Nov 2018 → Jun 2026 overdue	B-cell chronic lymphocytic leukemia	Miltenyi Biomedicine GmbH	Active not recruiting	No outcome recorded
Phase 1	NCT03030976	Mar 2017 → Jan 2018	systemic lupus erythematosus	Shanghai GeneChem Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT01087294	Aug 2010 → Mar 2024	B-cell neoplasm, Hodgkins lymphoma, non-Hodgkin lymphoma	National Cancer Institute (NCI)	Completed	No outcome recorded

Phase 1/27 trials
Phase 1/2	NCT06821659	Mar 2025 → Dec 2027 expected	Sjogren syndrome, anti-neutrophil cytoplasmic antibody-associated vasculitis, idiopathic inflammatory myopathy, systemic lupus erythematosus +1	Peking University Third Hospital	Not yet recruiting	No outcome recorded
Phase 1/2	NCT06189157	Aug 2024 → Sep 2027 expected	systemic lupus erythematosus	Miltenyi Biomedicine GmbH	Recruiting	No outcome recorded
Phase 1/2	NCT02737085	Mar 2016 → Dec 2019	diffuse large B-cell lymphoma	Southwest Hospital, China	Unknown	No outcome recorded
Phase 1/2	NCT02672501	Jan 2016 → Jun 2018	lymphoid leukemia	Shanghai GeneChem Co., Ltd.	Unknown	No outcome recorded
Phase 1/2	NCT02547948	Sep 2015 → Aug 2016	lymphoma	Fuda Cancer Hospital, Guangzhou	Withdrawn	No outcome recorded
Phase 1/2	NCT02247609	Jan 2014 → Oct 2016	B-cell non-Hodgkin lymphoma	Peking University	Unknown	No outcome recorded
Phase 1/2	NCT00924326	Feb 2009 → Sep 2015	mantle cell lymphoma, primary mediastinal large B-cell lymphoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 24 trials
Phase 2	NCT07493395	Jun 2026 → Jun 2028 expected	systemic sclerosis	University Hospital, Montpellier	Recruiting	No outcome recorded
Phase 2	NCT05744037	Jan 2023 → Jan 2025	B-cell non-Hodgkin lymphoma	The Affiliated Hospital of Xuzhou Medical University	Unknown	No outcome recorded
Phase 2	NCT05648019	Mar 2022 → Dec 2025 overdue	B-cell acute lymphoblastic leukemia, adult acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia, large B-cell lymphoma	KK Women's and Children's Hospital	Recruiting	No outcome recorded
Phase 2	NCT03321123	Dec 2017 → Jul 2019	B-cell acute lymphoblastic leukemia	Shanghai Children's Medical Center	Unknown	No outcome recorded
Phase not applicable3 trials
—	NCT07371403	Feb 2026 → Jan 2029 expected	B-cell acute lymphoblastic leukemia	King Hussein Cancer Center	Recruiting	No outcome recorded
—	NCT06508775	May 2024 → Dec 2040 expected	childhood acute lymphoblastic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, melanoma	Miltenyi Biomedicine GmbH	Recruiting	No outcome recorded
—	NCT06503237	Nov 2023 → Mar 2026 overdue	rheumatoid arthritis	The First Affiliated Hospital of University of Science and Technology of China	Recruiting	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT05952804 Background	Jun 2024 → Jul 2028 expected	hematopoietic and lymphoid cell neoplasm	Fred Hutchinson Cancer Center	Recruiting	No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 34 sources stand behind the page.

Field	Value	Cited text
Known as	anti-CD19 CAR-T cells	“A single intravenous infusion of autologous anti-CD19 CAR-T cells will be administered on Day 0 at a target dose of 1 × 10⁶ CAR-T cells/kg.” NCT07493395 ↗ 23 “The 10 treated patients received a single infusion of allogeneic anti-CD19-CAR T cells.” PMID 24055823 ↗ Sep 2013 “adoptive transfer of anti-CD19 CAR T cells is now being tested in clinical trials.” PMID 23546520 ↗ Apr 2013 NCT06821659 ↗ NCT06222853 ↗ NCT06792344 ↗ NCT02672501 ↗ NCT06503237 ↗ NCT06027957 ↗ NCT06756321 ↗ NCT06420154 ↗ NCT05744037 ↗ NCT04289220 ↗ NCT05648019 ↗ NCT04545762 ↗ NCT02737085 ↗ NCT07544225 ↗ NCT06532630 ↗ NCT05952804 ↗ NCT03030976 ↗ NCT06227026 ↗ NCT02247609 ↗ NCT06375161 ↗ NCT06842589 ↗
Known as	anti-CD19-CAR-transduced T cells	“These anti-CD19-CAR-transduced T cells specifically recognize a variety of CD19+ target cells and kill primary chronic lymphocytic leukemia (CLL) cells in vitro.” NCT01087294 ↗
Known as	CD19 CAR T-cells	“For Biological: CD19 CAR T-cells” NCT06027957 ↗
Known as	CD19-targeting CAR T Cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02547948 ↗
Known as	MB-CART19.1	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03853616 ↗ 5 NCT03321123 ↗ NCT06508775 ↗ NCT07371403 ↗ NCT07137494 ↗ NCT06189157 ↗
Known as	UWD-CD19	“anti-CD19 CAR-T (UWD-CD19)” NCT06821659 ↗
Action	Deplete	“anti-CD19-CAR-transduced T cells have great promise to improve the treatment of B-cell malignancies because of a potent ability to eradicate CD19(+) cells in vivo” PMID 22160384 ↗ Dec 2011
Modality	Cell therapy	“adoptive transfer of anti-CD19 CAR T cells is now being tested in clinical trials.” PMID 23546520 ↗ Apr 2013
Route	Intravenous	“Cells will be infused via intravenous (IV) on the Patient Care Unit over 20-30 minutes.” NCT00924326 ↗
Target	CD19	“We have constructed a retroviral vector that encodes an anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) that recognizes the CD19 antigen.” NCT00924326 ↗